Beta
ManageSearchChatDiscover
322823

SYNERGIC EFFECT OF COMBINATION THERAPY FOR TREATMENT OF COVID-19 ASSOCIATED MUCORMYCOSIS

Article

Last updated: 04 Jan 2025

OverviewSimilar Items

Subjects

-

Tags

-

Abstract

Mucormycosis is an invasive fungal infection that may cause significant morbidity and mortality. The main target organs of mucormycosis infection are the parental sinusitis, orbital cavity, and the brain tissue. It has come to focus during the last few years in context of COVID-19 infection. COVID 19 patients are highly susceptible to fungal infections as they are always immunosuppressed. Prompt eradication of mucormycosis infection by means of anti-fungal therapy in addition to surgical debridement is the standard of care. We questioned if combination antifungal therapy may offer a more effective, yet less toxic, therapy for mucormycosis. We reviewed the literature covering antifungal agents for mucormycosis, whether as monotherapy or in combination. We concluded that combination therapy could be a promising treatment for mucormycosis, particularly in cases associated with COVID-19 infection. This combination could decrease the nephrotoxicity caused by amphotericin B, the main choice in treating mucormycosis, and, on other hand, enhance its therapeutic efficacy.

DOI

10.21608/bfsa.2023.230289.1875

Keywords

COVID-19-associated mucormycosis, Antifungal, Combination therapy

Authors

First Name

Sahar

Last Name

Fayez

MiddleName

Mostafa

Affiliation

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6th University, Giza, Egypt

Email

saharmfayez@o6u.edu.eg

City

October

Orcid

0000-0002-0001-6147

First Name

Fatma

Last Name

Abobakr

MiddleName

-

Affiliation

Egyptian Drug Authority (EDA), Giza, Egypt

Email

fatma_abobakr89@yahoo.com

City

-

Orcid

-

First Name

Ahmed

Last Name

Rashed

MiddleName

Mohamed

Affiliation

Department of Internal medicine, Faculty of Medicine, Fayoum University, Cairo, Egypt

Email

amr14@fayoum.edu.eg

City

October

Orcid

-

First Name

Mohamed

Last Name

El-Nabarawi

MiddleName

Ahmed

Affiliation

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Email

mohamed.elnabarawi@pharma.cu.edu.eg

City

Cairo

Orcid

-

First Name

Mahmoud

Last Name

Teaima

MiddleName

Hassan

Affiliation

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt

Email

mahmoud.teaima@pharma.cu.edu.eg

City

Cairo

Orcid

-

First Name

Rania

Last Name

El-Dahmy

MiddleName

Moataz

Affiliation

Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, October 6th University, Giza, Egypt

Email

rania-moataz@o6u.edu.eg

City

October

Orcid

-

Volume

47

Article Issue

1

Related Issue

47734

Issue Date

2024-06-01

Receive Date

2023-08-21

Publish Date

2024-06-01

Page Start

21

Page End

40

Print ISSN

1110-0052

Online ISSN

3009-7703

Article File

BFSA_Volume 47_Issue 1_Pages 21-40.pdf

PDF . 1.4MB

Link

https://bpsa.journals.ekb.eg/article_322823.html

Detail API

https://bpsa.journals.ekb.eg/service?article_code=322823

Order

2

Type

Review Article

Type Code

2,839

Publication Type

Journal

Publication Title

Bulletin of Pharmaceutical Sciences Assiut University

Publication Link

https://bpsa.journals.ekb.eg/

MainTitle

SYNERGIC EFFECT OF COMBINATION THERAPY FOR TREATMENT OF COVID-19 ASSOCIATED MUCORMYCOSIS

Details

Type

Article

Created At

25 Dec 2024